ASCO 2013 Video: Can we target KRAS effectively in advanced NSCLC? - 1257711

Wed, 07/03/2013 - 09:03

In today's ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

You can view the video here:

We welcome your questions and comments here.

Forum moderator

Revision log message
Created by FeedsNodeProcessor